[Edaily Reporter Hyera Lee ] NANO. Co., Ltd.(187790)announced on the 22nd that it is pursuing a deal to supply selective catalytic reduction (SCR) catalysts for heat recovery steam generators (HRSGs) in a domestic power plant project that will utilize large gas turbines from a global turbine manufacturer. NANO. Co., Ltd. CI. (Photo courtesy of NANO. Co., Ltd.) This project involves the installation of large gas turbines from a global turbine manufacturer at an eco-friendly power plant in South Korea. The client will be responsible for the design and engineering of the SCR catalyst, while NANO. Co., Ltd. will produce and supply the catalyst. Gas turbine power plants generate high-temperature, high-velocity exhaust gases, requiring a high level of catalyst strength and denitrification efficiency. NANO. Co., Ltd. plans to produce and supply high-strength, high-efficiency SCR catalysts for HRSGs tailored to these conditions. Through this project, NANO. Co., Ltd. aims to enhance product reliability and supply stability by leveraging its manufacturing capabilities for SCR catalysts for large gas turbines, while also expanding its penetration of the global gas turbine power generation market for AI data centers, building on its growing track record of supplying gas turbine power plants. A NANO. Co., Ltd. official stated, “We will ensure a stable supply of high-performance catalysts optimized for gas turbine operating conditions and strengthen our penetration of the global large-scale gas turbine market, including AI data centers.”
KBI METAL CO., LTD.’s Eumseong Plant Office Building. (Photo courtesy of KBI Group)
KBI METAL CO., LTD. posted its highest-ever cumulative operating profit for the first three quarters of this year,…
Lotte Group will hold board meetings for its affiliates as early as the 16th to carry out its regular executive reshuffle. Following last year’s replacement of 20 chief executive officers (CEOs), all …
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…
